Modified Project Summary/Abstract Section
PROJECT SUMMARY/ABSTRACT
Lung cancer screening using low-dose computed tomography significantly reduces lung cancer mortality, the
leading cause of cancer mortality in the United States. Despite its life-saving potential, lung cancer screening
uptake remains extremely low among eligible populations (about 5%). Lung cancer screening utilization is even
lower among populations that experience a disproportionate burden of lung cancer (e.g., Black and low-income
Americans). In November 2021, the U.S. Preventive Services Task Force (USPSTF) called for more evidence
to increase equity in lung cancer screening uptake in their Annual Report to Congress. Yet, multilevel barriers
to lung cancer screening exist at the patient, provider, and health system levels. However, prior research
assessing these barriers is limited by inadequate racial, ethnic, and socioeconomic diversity among
participants and exclusion of key health care staff (e.g., nurses) who often champion screening programs.
Medical mistrust is another commonly reported screening barrier. Yet, mistrust is often studied as a patient-
level barrier, ignoring that mistrust arises from structures, such as racism in health care. Many health care
interventions also lack trustworthiness, partly because they are often designed without community input. Little
is known about how screening barriers can be addressed through implementation strategies that center equity
and have an explicit goal to earn patient trust. Through three specific aims, this study will address these
knowledge gaps. These aims are to: 1) identify multilevel barriers and facilitators to the equitable
implementation of lung cancer screening (K99 phase), 2) engage with community advisors and key
stakeholders to identify multilevel implementation strategies to promote equity in lung cancer screening (K99
phase), and 3) pilot test the feasibility of multilevel implementation strategies designed to equitably improve
lung cancer screening uptake (one at the patient level and one at the provider/system level, R00 phase). To
complete these research aims, the candidate (Dr. Jennifer Richmond) requires didactic and mentored training
in lung cancer leadership, implementation science, and methods for designing/evaluating multilevel health
equity interventions. Dr. Richmond has assembled an outstanding mentoring team (Drs. Melinda Aldrich,
Consuelo Wilkins, Eric Grogan, and Carolyn Audet) with collective expertise in these areas to help her achieve
the research and training goals. Overall, this innovative study will be among the first to respond to the USPSTF
call for evidence to increase lung cancer screening equity. It will also lay the groundwork for a R01 application
to evaluate the intervention pilot tested in this study. With support from her mentors and the exceptional
training and research environment at Vanderbilt University Medical Center, Dr. Richmond will reach her long-
term goal of transitioning to independence and becoming a national leader in lung cancer equity research.